Free Trial

MarketBeat Instant News Alerts

Ibotta logo with Services background

Ibotta, Inc. (NYSE:IBTA) Given Average Rating of "Moderate Buy" by Analysts

MarketBeat

Ibotta, Inc. (NYSE:IBTA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The

NYSE:IBTA
Read Ibotta, Inc. (NYSE:IBTA) Given Average Rating of "Moderate Buy" by Analysts
Shake Shack logo with Retail/Wholesale background

Shake Shack (NYSE:SHAK) Given Hold Rating at TD Securities

MarketBeat

TD Securities reissued a "hold" rating and issued a $105.00 price objective on shares of Shake Shack in a report on Monday.

NYSE:SHAK
Read Shake Shack (NYSE:SHAK) Given Hold Rating at TD Securities
ACADIA Pharmaceuticals logo with Medical background

Needham & Company LLC Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

MarketBeat

Needham & Company LLC raised their price objective on ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday.

NASDAQ:ACAD
Read Needham & Company LLC Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock
Medtronic logo with Medical background

Needham & Company LLC Reiterates Hold Rating for Medtronic (NYSE:MDT)

MarketBeat

Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a research note on Monday.

NYSE:MDT
Read Needham & Company LLC Reiterates Hold Rating for Medtronic (NYSE:MDT)
Merus logo with Medical background

Merus' (MRUS) "Buy" Rating Reaffirmed at Needham & Company LLC

MarketBeat

Needham & Company LLC reissued a "buy" rating and issued a $75.00 price target on shares of Merus in a research report on Monday.

NASDAQ:MRUS
Read Merus' (MRUS) "Buy" Rating Reaffirmed at Needham & Company LLC
Upstart logo with Finance background

Upstart's (UPST) Buy Rating Reaffirmed at Needham & Company LLC

MarketBeat

Needham & Company LLC reaffirmed a "buy" rating and set a $70.00 price objective on shares of Upstart in a research report on Monday.

NASDAQ:UPST
Read Upstart's (UPST) Buy Rating Reaffirmed at Needham & Company LLC

Trending News

All MarketBeat Instant News Alerts

LightPath Technologies logo with Computer and Technology background

LightPath Technologies (NASDAQ:LPTH) Given Buy Rating at HC Wainwright

MarketBeat
NASDAQ:LPTH
Read LightPath Technologies (NASDAQ:LPTH) Given Buy Rating at HC Wainwright
Bit Digital logo with Business Services background

Bit Digital (NASDAQ:BTBT) Earns "Buy" Rating from HC Wainwright

MarketBeat
NASDAQ:BTBT
Read Bit Digital (NASDAQ:BTBT) Earns "Buy" Rating from HC Wainwright
Eledon Pharmaceuticals logo with Medical background

Velan Capital Investment Management LP Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

MarketBeat
NASDAQ:ELDN
Read Velan Capital Investment Management LP Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Perspective Therapeutics logo with Medical background

Velan Capital Investment Management LP Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

MarketBeat
NYSE:CATX
Read Velan Capital Investment Management LP Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)
Nurix Therapeutics logo with Medical background

Velan Capital Investment Management LP Invests $1.84 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

MarketBeat
NASDAQ:NRIX
Read Velan Capital Investment Management LP Invests $1.84 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Replimune Group logo with Medical background

Velan Capital Investment Management LP Acquires Shares of 181,367 Replimune Group, Inc. (NASDAQ:REPL)

MarketBeat
NASDAQ:REPL
Read Velan Capital Investment Management LP Acquires Shares of 181,367 Replimune Group, Inc. (NASDAQ:REPL)
Verona Pharma logo with Medical background

Velan Capital Investment Management LP Acquires New Stake in Verona Pharma plc (NASDAQ:VRNA)

MarketBeat
NASDAQ:VRNA
Read Velan Capital Investment Management LP Acquires New Stake in Verona Pharma plc (NASDAQ:VRNA)
Zevra Therapeutics logo with Medical background

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position

MarketBeat
NASDAQ:ZVRA
Read Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position
SpringWorks Therapeutics logo with Medical background

Velan Capital Investment Management LP Makes New $6.70 Million Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

MarketBeat
NASDAQ:SWTX
Read Velan Capital Investment Management LP Makes New $6.70 Million Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Protara Therapeutics logo with Medical background

Velan Capital Investment Management LP Buys 1,005,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

MarketBeat
NASDAQ:TARA
Read Velan Capital Investment Management LP Buys 1,005,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)
Tourmaline Bio logo with Medical background

Tourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LP

MarketBeat
NASDAQ:TRML
Read Tourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LP
Praxis Precision Medicines logo with Medical background

Velan Capital Investment Management LP Sells 50,666 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

MarketBeat
NASDAQ:PRAX
Read Velan Capital Investment Management LP Sells 50,666 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Cipher Mining logo with Business Services background

Vennlight Capital Management LP Takes $1.37 Million Position in Cipher Mining Inc. (NASDAQ:CIFR)

MarketBeat
NASDAQ:CIFR
Read Vennlight Capital Management LP Takes $1.37 Million Position in Cipher Mining Inc. (NASDAQ:CIFR)
TeraWulf logo with Finance background

Vennlight Capital Management LP Purchases Shares of 351,994 TeraWulf Inc. (NASDAQ:WULF)

MarketBeat
NASDAQ:WULF
Read Vennlight Capital Management LP Purchases Shares of 351,994 TeraWulf Inc. (NASDAQ:WULF)
Hut 8 logo with Finance background

Vennlight Capital Management LP Invests $2.41 Million in Hut 8 Corp. (NASDAQ:HUT)

MarketBeat
NASDAQ:HUT
Read Vennlight Capital Management LP Invests $2.41 Million in Hut 8 Corp. (NASDAQ:HUT)
MacroGenics logo with Medical background

MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Vestal Point Capital LP

MarketBeat
NASDAQ:MGNX
Read MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Vestal Point Capital LP
Verve Therapeutics logo with Medical background

Verve Therapeutics, Inc. (NASDAQ:VERV) Position Raised by Vestal Point Capital LP

MarketBeat
NASDAQ:VERV
Read Verve Therapeutics, Inc. (NASDAQ:VERV) Position Raised by Vestal Point Capital LP
Sutro Biopharma logo with Medical background

2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LP

MarketBeat
NASDAQ:STRO
Read 2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LP
Nurix Therapeutics logo with Medical background

Vestal Point Capital LP Acquires 60,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

MarketBeat
NASDAQ:NRIX
Read Vestal Point Capital LP Acquires 60,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Establishment Labs logo with Medical background

Vestal Point Capital LP Raises Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

MarketBeat
NASDAQ:ESTA
Read Vestal Point Capital LP Raises Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)
GreenX Metals logo with Basic Materials background

GreenX Metals (LON:GRX) Shares Up 7.9% - Time to Buy?

MarketBeat
LON:GRX
Read GreenX Metals (LON:GRX) Shares Up 7.9% - Time to Buy?
Protagonist Therapeutics logo with Medical background

Protagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC Wainwright

MarketBeat
NASDAQ:PTGX
Read Protagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC Wainwright
Aldeyra Therapeutics logo with Medical background

Aldeyra Therapeutics' (ALDX) "Buy" Rating Reiterated at HC Wainwright

MarketBeat
NASDAQ:ALDX
Read Aldeyra Therapeutics' (ALDX) "Buy" Rating Reiterated at HC Wainwright
OptiNose logo with Medical background

HC Wainwright Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)

MarketBeat
NASDAQ:OPTN
Read HC Wainwright Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)

Featured Articles and Offers

Sector News